{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T03:04:40Z","timestamp":1776827080820,"version":"3.51.2"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T00:00:00Z","timestamp":1627862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T00:00:00Z","timestamp":1627862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cancer chemotherapy usually improves clinical outcomes in patients with advanced pancreatic cancer (APC), but can also cause moderate-to-severe adverse events (AEs). We investigated the relationship between moderate-to-severe AEs and quality of life (QOL) in patients with APC who received outpatient chemotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We recruited APC patients who received outpatient chemotherapy in Gifu University Hospital between September 2017 and December 2018. Adverse events related to chemotherapy were assessed by a pharmacist collaborating with a physician using common terminology criteria for AEs (CTCAE) ver 4.0, and QOL of patients was self-assessed by patients using the five-level EuroQol five-dimensional questionnaire (EQ-5D-5L Japanese edition 2). Associations between the EQ-5D-5L utility value and serious AEs were assessed using proportional odds logistic regression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 59 patients who received 475 chemotherapy cycles were included. The proportional odds logistic regression indicated that grade\u2009\u2265\u20092 anorexia, pain and peripheral neuropathy were significantly correlated with a decreased EQ-5D-5L utility value. Pharmaceutical intervention for these AEs significantly improved the patients\u2019 EQ-5D-5L utility value.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Anorexia, pain and peripheral neuropathy were significantly associated with a decrease in QOL. It is assumed that appropriate pharmaceutical intervention with particular emphasis on these AEs can improve the QOL of pancreatic cancer patients receiving outpatient chemotherapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40780-021-00210-1","type":"journal-article","created":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T23:03:25Z","timestamp":1627859005000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Anorexia, pain and peripheral neuropathy are associated with a decrease in quality of life in patients with advanced pancreatic cancer receiving outpatient chemotherapy \u2014 a retrospective observational study"],"prefix":"10.1186","volume":"7","author":[{"given":"Hironori","family":"Fujii","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maaya","family":"Koda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiori","family":"Sadaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Ohata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Kato-Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotoshi","family":"Iihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuji","family":"Iwashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahito","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,2]]},"reference":[{"issue":"11","key":"210_CR1","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1111\/cas.12525","volume":"105","author":"Y Ito","year":"2014","unstructured":"Ito Y, Miyashiro I, Ito H, Hosono S, Chihara D, Nakata-Yamada K, et al. Long-term survival and conditional survival of cancer patients in Japan using population-based cancer registry data. Cancer Sci. 2014;105(11):1480\u20136. https:\/\/doi.org\/10.1111\/cas.12525.","journal-title":"Cancer Sci"},{"issue":"19","key":"210_CR2","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouch\u00e9 O, Guimbaud R, B\u00e9couarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1011923.","journal-title":"N Engl J Med"},{"issue":"18","key":"210_CR3","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691\u2013703. https:\/\/doi.org\/10.1056\/NEJMoa1304369.","journal-title":"N Engl J Med"},{"issue":"67","key":"210_CR4","doi-asserted-by":"publisher","first-page":"111346","DOI":"10.18632\/oncotarget.22795","volume":"8","author":"K Yoshida","year":"2017","unstructured":"Yoshida K, Iwashita T, Uemura S, Maruta A, Okuno M, Ando N, et al. A multicenter prospective phase II study of first-line modified FOLFIRINOX for unresectable advanced pancreatic cancer. Oncotarget. 2017;8(67):111346\u201355. https:\/\/doi.org\/10.18632\/oncotarget.22795.","journal-title":"Oncotarget"},{"key":"210_CR5","doi-asserted-by":"crossref","unstructured":"Mita N, Iwashita T, Uemura S, Yoshida K, Iwasa Y, Ando N, et al. Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure. J Clin Med. 2019;8(6):761.","DOI":"10.3390\/jcm8060761"},{"issue":"13","key":"210_CR6","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1200\/JCO.2012.43.3680","volume":"31","author":"H Ueno","year":"2013","unstructured":"Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol. 2013;31(13):1640\u20138. https:\/\/doi.org\/10.1200\/JCO.2012.43.3680.","journal-title":"J Clin Oncol"},{"issue":"15","key":"210_CR7","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","volume":"25","author":"MJ Moore","year":"2007","unstructured":"Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada clinical trials group. J Clin Oncol. 2007;25(15):1960\u20136. https:\/\/doi.org\/10.1200\/JCO.2006.07.9525.","journal-title":"J Clin Oncol"},{"issue":"12","key":"210_CR8","doi-asserted-by":"publisher","first-page":"5943","DOI":"10.1007\/s00520-020-05443-8","volume":"28","author":"C Hirose","year":"2020","unstructured":"Hirose C, Fujii H, Iihara H, Ishihara M, Nawa-Nishigaki M, Kato-Hayashi H, et al. Real-world data of the association between quality of life using the EuroQol 5 dimension 5 level utility value and adverse events for outpatient cancer chemotherapy. Support Care Cancer. 2020;28(12):5943\u201352. https:\/\/doi.org\/10.1007\/s00520-020-05443-8.","journal-title":"Support Care Cancer"},{"issue":"4","key":"210_CR9","doi-asserted-by":"publisher","first-page":"e0124169","DOI":"10.1371\/journal.pone.0124169","volume":"10","author":"T Tachi","year":"2015","unstructured":"Tachi T, Teramachi H, Tanaka K, Asano S, Osawa T, Kawashima A, et al. The impact of outpatient chemotherapy-related adverse events on the quality of life of breast cancer patients. PLoS One. 2015;10(4):e0124169. https:\/\/doi.org\/10.1371\/journal.pone.0124169.","journal-title":"PLoS One"},{"issue":"9","key":"210_CR10","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1007\/s00520-019-4659-x","volume":"27","author":"M de Mol","year":"2019","unstructured":"de Mol M, Visser S, den Oudsten BL, Lodder P, van Walree N, Belderbos H, et al. Frequency of low-grade adverse events and quality of life during chemotherapy determine patients\u2019 judgement about treatment in advanced-stage thoracic cancer. Support Care Cancer. 2019;27(9):3563\u201372. https:\/\/doi.org\/10.1007\/s00520-019-4659-x.","journal-title":"Support Care Cancer"},{"issue":"24","key":"210_CR11","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1200\/JCO.2018.78.9636","volume":"36","author":"DPS Sohal","year":"2018","unstructured":"Sohal DPS, Kennedy EB, Khorana A, Copur MS, Crane CH, Garrido-Laguna I, et al. Metastatic pancreatic Cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36(24):2545\u201356. https:\/\/doi.org\/10.1200\/JCO.2018.78.9636.","journal-title":"J Clin Oncol"},{"key":"210_CR12","unstructured":"US Department of Health and Human Services, National Institutes of Health National Cancer Institute Common terminology criteria for adverse events (CTCAE) version 4.0. (2009) Available online: https:\/\/www.eortc.be\/services\/doc\/ctc\/ (Accessed 19 July 2019)."},{"issue":"5","key":"210_CR13","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.jval.2016.03.1834","volume":"19","author":"T Shiroiwa","year":"2016","unstructured":"Shiroiwa T, Ikeda S, Noto S, Igarashi A, Fukuda T, Saito S, et al. Comparison of value set based on DCE and\/or TTO data: scoring for EQ-5D-5L health states in Japan. Value Health. 2016;19(5):648\u201354. https:\/\/doi.org\/10.1016\/j.jval.2016.03.1834.","journal-title":"Value Health"},{"issue":"10","key":"210_CR14","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727\u201336. https:\/\/doi.org\/10.1007\/s11136-011-9903-x.","journal-title":"Qual Life Res"},{"issue":"10","key":"210_CR15","doi-asserted-by":"publisher","first-page":"678","DOI":"10.2490\/jjrm1963.41.678","volume":"41","author":"T Okamoto","year":"2004","unstructured":"Okamoto T, Hashimoto K, Ohashi M, Nakachi T, Ishii A, Miyano S. Survey on health-related quality of life (HRQOL) and cost-effectiveness for rehabilitation hospital inpatients by EuroQOL. Jpn JRehabil Med. 2004;41(10):678\u201385. (In Japanese). https:\/\/doi.org\/10.2490\/jjrm1963.41.678.","journal-title":"Jpn JRehabil Med"},{"issue":"31","key":"210_CR16","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1200\/JCO.2010.34.4614","volume":"29","author":"E Basch","year":"2011","unstructured":"Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29(31):4189\u201398. https:\/\/doi.org\/10.1200\/JCO.2010.34.4614.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"210_CR17","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1007\/s11739-010-0448-8","volume":"5","author":"S Mercadante","year":"2010","unstructured":"Mercadante S. Management of cancer pain. Intern Emerg Med. 2010;5(Suppl 1):S31\u20135.","journal-title":"Intern Emerg Med"},{"issue":"13","key":"210_CR18","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1001\/jama.2013.2813","volume":"309","author":"EM Smith","year":"2013","unstructured":"Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309(13):1359\u201367. https:\/\/doi.org\/10.1001\/jama.2013.2813.","journal-title":"JAMA."},{"issue":"7","key":"210_CR19","first-page":"2927","volume":"30","author":"MW Saif","year":"2010","unstructured":"Saif MW, Syrigos K, Kaley K, Isufi I. Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy. Anticancer Res. 2010;30(7):2927\u201333.","journal-title":"Anticancer Res"},{"issue":"3-4","key":"210_CR20","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1159\/000328449","volume":"80","author":"JH Yi","year":"2011","unstructured":"Yi JH, Lee J, Park SH, Lee KT, Lee JK, Lee KH, et al. A prognostic model to predict clinical outcomes with first-line gemcitabine-based chemotherapy in advanced pancreatic cancer. Oncology. 2011;80(3-4):175\u201380. https:\/\/doi.org\/10.1159\/000328449.","journal-title":"Oncology."},{"issue":"2","key":"210_CR21","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/cam4.204","volume":"3","author":"P Xue","year":"2014","unstructured":"Xue P, Kanai M, Mori Y, Nishimura T, Uza N, Kodama Y, et al. Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients. Cancer Med. 2014;3(2):406\u201315. https:\/\/doi.org\/10.1002\/cam4.204.","journal-title":"Cancer Med."},{"issue":"3","key":"210_CR22","doi-asserted-by":"publisher","first-page":"643","DOI":"10.3349\/ymj.2013.54.3.643","volume":"54","author":"KJ Lee","year":"2013","unstructured":"Lee KJ, Yi SW, Chung MJ, Park SW, Song SY, Chung JB, et al. Serum CA 19-9 and CEA levels as a prognostic factor in pancreatic adenocarcinoma. Yonsei Med J. 2013;54(3):643\u20139. https:\/\/doi.org\/10.3349\/ymj.2013.54.3.643.","journal-title":"Yonsei Med J"},{"issue":"6","key":"210_CR23","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3177\/jnsv.64.445","volume":"64","author":"S Onishi","year":"2018","unstructured":"Onishi S, Shiraki M, Nishimura K, Hanai T, Moriwaki H, Shimizu M. Prevalence of sarcopenia and its relationship with nutritional state and quality of life in patients with digestive diseases. J Nutr Sci Vitaminol. 2018;64(6):445\u201353. https:\/\/doi.org\/10.3177\/jnsv.64.445.","journal-title":"J Nutr Sci Vitaminol"},{"key":"210_CR24","first-page":"12","volume":"22","author":"R Pezzilli","year":"2020","unstructured":"Pezzilli R, Caccialanza R, Capurso G, Brunetti O, Milella M, Falconi M. Pancreatic enzyme replacement therapy in pancreatic Cancer. Cancers (Basel). 2020;22:12.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"210_CR25","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3390\/nu9030243","volume":"9","author":"TM Gilliland","year":"2017","unstructured":"Gilliland TM, Villafane-Ferriol N, Shah KP, Shah RM, Tran Cao HS, Massarweh NN, et al. Nutritional and metabolic derangements in pancreatic Cancer and pancreatic resection. Nutrients. 2017;9(3):243. https:\/\/doi.org\/10.3390\/nu9030243.","journal-title":"Nutrients."},{"issue":"2","key":"210_CR26","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.critrevonc.2010.03.002","volume":"78","author":"KK Cheng","year":"2011","unstructured":"Cheng KK, Lee DT. Effects of pain, fatigue, insomnia, and mood disturbance on functional status and quality of life of elderly patients with cancer. Crit Rev Oncol Hematol. 2011;78(2):127\u201337. https:\/\/doi.org\/10.1016\/j.critrevonc.2010.03.002.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"210_CR27","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s10549-010-1278-0","volume":"125","author":"DL Hershman","year":"2011","unstructured":"Hershman DL, Weimer LH, Wang A, Kranwinkel G, Brafman L, Fuentes D, et al. Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat. 2011;125(3):767\u201374. https:\/\/doi.org\/10.1007\/s10549-010-1278-0.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"210_CR28","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1002\/cam4.1976","volume":"8","author":"LC Lu","year":"2019","unstructured":"Lu LC, Tsay SL, Chang SY, Chen CM, Liu CY. Daily activity, mood, and quality of life in colorectal cancer patients with chemotherapy-induced peripheral neuropathy: a mediation effect analysis. Cancer Med. 2019;8(3):963\u201371. https:\/\/doi.org\/10.1002\/cam4.1976.","journal-title":"Cancer Med"},{"key":"210_CR29","doi-asserted-by":"publisher","first-page":"2091960","DOI":"10.1155\/2019\/2091960","volume":"2019","author":"A Girach","year":"2019","unstructured":"Girach A, Julian TH, Varrassi G, Paladini A, Vadalouka A, Zis P. Quality of life in painful peripheral neuropathies: a systematic review. Pain Res Manag. 2019;2019:2091960.","journal-title":"Pain Res Manag"},{"issue":"1","key":"210_CR30","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12955-018-0989-5","volume":"16","author":"M Akhtari-Zavare","year":"2018","unstructured":"Akhtari-Zavare M, Mohd-Sidik S, Periasamy U, Rampal L, Fadhilah SI, Mahmud R. Determinants of quality of life among Malaysian cancer patients: a cross-sectional study. Health Qual Life Outcomes. 2018;16(1):163. https:\/\/doi.org\/10.1186\/s12955-018-0989-5.","journal-title":"Health Qual Life Outcomes"},{"key":"210_CR31","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/BSD.0000000000000446","volume":"29","author":"MG Maltenfort","year":"2016","unstructured":"Maltenfort MG. The minimally important clinical difference. Clin Spine Surg. 2016;29:383.","journal-title":"Clin Spine Surg"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-021-00210-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-021-00210-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-021-00210-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T23:17:30Z","timestamp":1627859850000},"score":1,"resource":{"primary":{"URL":"https:\/\/jphcs.biomedcentral.com\/articles\/10.1186\/s40780-021-00210-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,2]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["210"],"URL":"https:\/\/doi.org\/10.1186\/s40780-021-00210-1","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,2]]},"assertion":[{"value":"26 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study was carried out in accordance with the guidelines for human studies adopted by the Ethics Committee of the Gifu University Graduate School of Medicine and the Japanese Government, and approved by the Medical Review Board of Gifu University Graduate School of Medicine (approval no. 2019\u2013225 Institutional Review Board). Informed consent was not obtained because this was a retrospective observational study. We posted information (opt-out enrollment method) about this study on the website of the hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27"}}